Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T13:30:52.162Z.
Calculation as of: 2026-10-06T13:30:52.162Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: aba6dde202523e327e8df603f06c84cdc8b0caa676e2570b33753db7f555988b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Market Cap
$10.07M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$9.63M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$10.74M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Caring Brands, Inc. (CABR) | $10.27M | N/A | N/A | N/A | N/A |
| SeaStar Medical Holding Corporation (ICU)vs › | $10.07M | N/A | N/A | N/A | N/A |
| Cerenome, Inc. (CNSY)vs › | $10.74M | N/A | N/A | N/A | N/A |
| Lifeward Ltd. (LFWD)vs › | $10.75M | N/A | N/A | N/A | N/A |
| Ainos, Inc. (AIMD)vs › | $9.94M | N/A | N/A | N/A | N/A |
| BioVie Inc. (BIVI)vs › | $10.86M | N/A | N/A | N/A | N/A |
| Jasper Therapeutics, Inc. (JSPR)vs › | $9.63M | N/A | N/A | N/A | N/A |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $10.74M | N/A | N/A | N/A | N/A |
| HeartSciences Inc. (HSCS)vs › | $9.42M | N/A | N/A | N/A | N/A |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.21M | N/A | 42.18% | 42.18% | 42.18% |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
